Trial
NCT05491317
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genmab
Collaborators
BioNTech SE
Condition
Non-CNS Tumor
Intervention
GEN1042
Why stopped
After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02